IgE in Autoimmunity
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (30 November 2020) | Viewed by 13465
Special Issue Editor
Interests: IgE; basophils; autoimmunity; lupus nephritis; mast cells; translational research
Special Issue Information
Dear Colleagues,
Autoantibodies in autoimmune diseases are often described as major pathogenic factors. Depending on their isotype and/or their specificity, these autoantibodies can participate to either protective or deleterious pathophysiological mechanisms in various autoimmune diseases. IgE is well recognized as a pathogenic factor in IgE-mediated allergic diseases. Research from the last couple of decades could also demonstrate their key role in some autoimmune diseases. Some studies have identified total IgE and autoreactive IgE as involved in pathophysiology, as strong diagnostic and prognostic biomarkers, and/or as valuable therapeutic targets. Indeed, anti-IgE monoclonal antibody Omalizumab was tested in various autoimmune diseases and often showed promising therapeutic value. This Special Issue of Antibodies focuses on some autoimmune diseases where autoantibodies of the IgE isotype have been evidenced, with specific emphasis on different pathogenic mechanisms (specificity, immune complexes, cell types involved in their pathogenic effects, etc.), potential therapeutic targeting, and critical information that can be derived from the study of IgE autoantibodies.
Dr. Nicolas Charles
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Autoreactive IgE
- IgE-mediated pathophysiology
- Autoimmune diseases and related mechanisms
- Type 2 immunity-driven autoimmune disease exacerbation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
